166 related articles for article (PubMed ID: 16690468)
21. [Familial type III hyperlipoproteinemia].
Eto M; Saito M
Nihon Rinsho; 2013 Sep; 71(9):1590-4. PubMed ID: 24205719
[TBL] [Abstract][Full Text] [Related]
22. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia.
Hoffmann MM; Scharnagl H; Köster W; Winkler K; Wieland H; März W
Clin Chim Acta; 2001 Jan; 303(1-2):41-8. PubMed ID: 11163021
[TBL] [Abstract][Full Text] [Related]
24. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
Hoffer MJ; Niththyananthan S; Naoumova RP; Kibirige MS; Frants RR; Havekes LM; Thompson GR
Atherosclerosis; 1996 Aug; 124(2):183-9. PubMed ID: 8830931
[TBL] [Abstract][Full Text] [Related]
26. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients.
Feussner G; Wagner A; Kohl B; Ziegler R
Clin Investig; 1993 May; 71(5):362-6. PubMed ID: 8508005
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
Smelt AH; de Beer F
Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
[TBL] [Abstract][Full Text] [Related]
29. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
[TBL] [Abstract][Full Text] [Related]
30. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
Saito M; Eto M; Kaku K
Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
[TBL] [Abstract][Full Text] [Related]
31. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
Gregg RE; Ghiselli G; Brewer HB
J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
34. Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency.
Paquette M; Bernard S; Paré G; Baass A
J Clin Endocrinol Metab; 2022 Jan; 107(2):538-548. PubMed ID: 34467996
[TBL] [Abstract][Full Text] [Related]
35. The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter.
Wierzbicki AS; Hardman TC; Cheung J; Lambert-Hammill M; Patel S; Morrish Z; Lumb PJ; Lant AF
Am J Hypertens; 2002 Jul; 15(7 Pt 1):633-7. PubMed ID: 12118912
[TBL] [Abstract][Full Text] [Related]
36. A simplified diagnosis algorithm for dysbetalipoproteinemia.
Paquette M; Bernard S; Blank D; Paré G; Baass A
J Clin Lipidol; 2020; 14(4):431-437. PubMed ID: 32631794
[TBL] [Abstract][Full Text] [Related]
37. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia.
Ghiselli G; Schaefer EJ; Zech LA; Gregg RE; Brewer HB
J Clin Invest; 1982 Aug; 70(2):474-7. PubMed ID: 7096573
[TBL] [Abstract][Full Text] [Related]
38. Familial apolipoprotein E deficiency.
Schaefer EJ; Gregg RE; Ghiselli G; Forte TM; Ordovas JM; Zech LA; Brewer HB
J Clin Invest; 1986 Nov; 78(5):1206-19. PubMed ID: 3771793
[TBL] [Abstract][Full Text] [Related]
39. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
[TBL] [Abstract][Full Text] [Related]
40. Type III hyperlipoproteinemia acquired by liver transplantation.
März W; Peschke B; Ruzicka V; Siekmeier R; Gross W; Schoeppe W; Scheuermann E
Transplantation; 1993 Feb; 55(2):284-8. PubMed ID: 8434377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
